SEC Comment Letter 0000000000-22-013955 to MAIA Biotechnology, Inc. (MAIA) (CIK 0001878313) (MAIA)
MAIA Biotechnology, Inc. (MAIA) (CIK 0001878313)
Date: Dec. 28, 2022 · CIK: 0001878313 · Accession: 0000000000-22-013955
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo December 28, 2022 Vlad Vitoc Chief Executive Officer MAIA Biotechnology, Inc. 444 West Lake Street, Suite 1700 Chicago, IL 60606 Re:MAIA Biotechnology, Inc. Draft Registration Statement on Form S-1 Submitted December 23, 2022 CIK No. 0001878313 Dear Vlad Vitoc: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Janeane Ferrari
Show Raw Text
United States securities and exchange commission logo
December 28, 2022
Vlad Vitoc
Chief Executive Officer
MAIA Biotechnology, Inc.
444 West Lake Street, Suite 1700
Chicago, IL 60606
Re:MAIA Biotechnology, Inc.
Draft Registration Statement on Form S-1
Submitted December 23, 2022
CIK No. 0001878313
Dear Vlad Vitoc:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Janeane Ferrari